BioMarin Pharmaceutical (BMRN) Debt to Equity Ratio

Current and historical debt to equity ratio values for BioMarin Pharmaceutical (BMRN) over the last 10 years.

Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $14.285B $1.314B
BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.